BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Cell culture experiments suggest inhibiting PARG alone or in combination with Chk1 inhibitors could help treat ovarian cancer. In three human ovarian cancer cell lines, a tool compound PARG...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Mar 27, 2018
Distillery Therapeutics

Infectious disease

...INDICATION: Viral infection Cell culture studies suggest inhibiting the TCP1, CCT2, CCT3, CCT4, CCT5 or CCT8...
...cell line showed knockdown of any of six genes encoding TRiC subunits -- TCP1, CCT2, CCT3...
...compared with scrambled siRNA. In HEK cells infected with reovirus, siRNA knockdown of CCT2 or CCT3...
BioCentury | Nov 10, 2017
Clinical News

Myovant and Takeda's relugolix meets in Phase III for uterine fibroid pain

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Myovant Sciences GmbH (NYSE:MYOV) reported top-line data from the Phase III TAK-385-3008 trial in 65 women with pain associated with uterine fibroids showing that once-daily 40 mg oral...
BioCentury | Oct 6, 2017
Clinical News

Myovant's relugolix meets in Phase III for uterine fibroids

Myovant Sciences GmbH (NYSE:MYOV) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said relugolix (TAK-385) met the primary endpoint of non-inferiority to leuprorelin acetate in reducing menstrual bleeding in the Japanese Phase III TAK-385/CCT-002 trial to...
BioCentury | Oct 3, 2017
Clinical News

Myovant's relugolix meets in Phase III for uterine fibroids

Myovant Sciences GmbH (NYSE:MYOV) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said relugolix (TAK-385) met the primary endpoint of non-inferiority to leuprorelin acetate in reducing menstrual bleeding in the Japanese Phase III TAK-385/CCT-002 trial to...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
BioCentury | Oct 10, 2016
Finance

Portfolio POC

Cancer Research Technology Ltd .'s push to move molecules into the clinic rather than out-license them at very early stages of development has paid its first dividends. Late last month, the Cancer Research Technology Pioneer...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: TCP1 containing ring complex (TRiC); T-complex 1 (TCP1; CCT1); chaperonin containing TCP1 subunit 3 (CCT3), CCT5; CCT7; CCT8; huntingtin (HTT)

...INDICATION: Huntington's disease (HD) Mouse and cell culture studies suggest promoting expression of TCP1 , CCT3...
...rat adrenal cell line expressing mutant human HTT , overexpression of the TRiC subunits TCP1, CCT3...
...primary cortical neurons from the mouse model, the TCP1 apical domain or lentiviral expression of CCT3...
Items per page:
1 - 10 of 31